Moreover, by analyzing FGFR1 mRNA expression, a stromal-rich tumor subtype has been identified that lacks both KRT5 and KRT20 mRNA expression and is almost resistant to upfront chemotherapy (0% pCR rate in FGFR1 high tumors vs. 66.7% pCR rate in FGFR1 low tumors). This evidence concerns the gene FGFR1 and neoplasm.